论文部分内容阅读
目的 检测第一和第二人体表皮生长因子受体 (humanepidermal-growth-factorreceptor 1and2 ,HER1 andHER2 )在肺癌组织中的表达 ,探讨HER1 、HER2 过度表达与肺癌临床病理的关系。 方法 用免疫组化法检测有随访资料的 70例肺癌 ( 4 3例鳞癌和 2 7例腺癌 )组织中HER1 、HER2 的表达。 结果 肺癌中HER1 、HER2 、HER1 +2 的过度表达率分别为 6 5 .7%、4 1 .4 %和 30 .0 %。肺癌中HER1 、HER2 、HERE1 +2 的过度表达与肺癌淋巴结转移、TNM分期、患者术后生存率相关。 结论 erbB1 、erbB2是晚期肺癌生长的调控基因 ,干预HER1 、HER2 、HER1 +2 的过度表达可能是治疗晚期肺癌的有效方法。
Objective To detect the expression of first and second human epidermal growth factor receptor 1 (HER1 and HER2) in lung cancer tissues, and to explore the relationship between HER1 and HER2 overexpression and clinical pathology of lung cancer. Methods Immunohistochemistry was used to detect the expression of HER1 and HER2 in 70 cases of lung cancer (43 cases of squamous cell carcinoma and 27 cases of adenocarcinoma) with follow-up data. Results Overexpression rates of HER1, HER2, and HER1 +2 in lung cancer were 65.7%, 41.4%, and 30.0%, respectively. Overexpression of HER1, HER2, HERE1 +2 in lung cancer was associated with lymph node metastasis, TNM staging, and postoperative survival. Conclusion erbB1 and erbB2 are the regulatory genes for the growth of advanced lung cancer. The intervention of HER1, HER2, HER1 +2 overexpression may be an effective method for the treatment of advanced lung cancer.